Your session is about to expire
← Back to Search
Psilocybin for Depression
Study Summary
This trial will study the effects of a single dose of psilocybin on adults with treatment-resistant depression and chronic suicidal ideation.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 18 and 65 years old.I have been diagnosed with Major Depressive Disorder.I have a history of a serious mental health condition like schizophrenia or bipolar disorder.My condition didn't improve after trying 2 different medications.
- Group 1: Psilocybin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this study accessible to individuals under 85 years of age?
"Patients that meet the age criteria of this study must be over 18 years old and not exceed 65 years."
Who is eligible to be enrolled in this medical research?
"To be eligible for this trial, participants must express suicidal thoughts and lie within the age range of 18 to 65. This research is taking on a maximum of 20 volunteers."
Is enrollment now open for this investigation?
"Verified. Clinicaltrials.gov states that this investigation, which was initially published on March 28th 2022, is currently enrolling test subjects. A single medical centre requires 20 volunteers for the study."
Has the Food and Drug Administration sanctioned Psilocybin for therapeutic use?
"Our team at Power believes that Psilocybin is moderately safe and has assigned it a score of 2. This rating takes into account the existing data on safety, but there is yet to be any conclusive information about efficacy."
What is the current size of the cohort under assessment in this trial?
"Affirmative. According to clinicaltrials.gov, this medical exploration is actively recruiting patients and was initially released on March 28th 2022. Its details were most recently updated on October 24th of the same year and it requires 20 individuals from a single centre for participation."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- Sheppard Pratt Health System: < 24 hours
Typically responds via
Share this study with friends
Copy Link
Messenger